Clinical TrialsThe first patient has been dosed in the Phase 1b trial evaluating paxalisib in combination with immunotherapies for triple-negative breast cancer.
Financial StabilityThe breast cancer study is funded by investigators and does not require capital investments from Kazia, which is beneficial for the company's financial stability.
Market OpportunitiesPaxalisib is being evaluated for treating resistant triple negative breast cancer, which presents a significant market opportunity, and data from this study could be impactful.